The 2026 paper reports no trial results yet because it is a protocol paper that publishes rationale and methods only. The linked acne trial had not started enrolling, so there were no patient outcomes to report. Secretome means the mix of signals released by stem cells, here tested as a topical add-on. The plan pairs daily HEXBIO multi-strain oral probiotic granules plus topical secretome with standard nightly acne medicine for adults with persistent disease.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What will the new trial actually test?
- Who is the study for?
- Why does earlier probiotic evidence stay limited?
- What are the open questions on secretome care?
What will the new trial actually test?
BMJ Open describes the 4 June 2026 paper as a double-blind randomised controlled trial protocol for oral probiotics plus topical secretome in acne vulgaris, with no efficacy results in that publication trial protocol. The design adds HEXBIO granules and topical secretome to nightly clindamycin-tretinoin applied to acne areas.
That add-on design matters for readers. Any future clearing must be separated from the effect of clindamycin-tretinoin alone. Blinding means neither patients nor assessors know who gets the extra products, which reduces bias in lesion counts.
Who is the study for?
The trial targets moderate-to-severe acne vulgaris, including adults with persistent disease. Adult persistence often means breakouts continue past the teen years across the lower face, jaw, chin, and trunk.
The ICH GCP Clinical Trials Registry lists entry NCT06925386 as "Not yet recruiting," which explains the missing outcomes registry entry. The same registry discussion points to rising antibiotic resistance and treatment failure in Indonesia as the reason for testing non-antibiotic adjuncts.
Why does earlier probiotic evidence stay limited?
Dermatology and Therapy reported that prior oral-probiotic acne trials were too few and too small for robust conclusions about effectiveness 2024 review. Small trials can miss real effects, overstate chance wins, and differ in strains, doses, and duration.
The same review raised probiotic quality concerns because strains are sensitive to temperature and humidity. A product stored warm, shipped slowly, or used past its handling limits may deliver fewer live strains than the label suggests.
What are the open questions on secretome care?
Our Dermatology Online reports that topical mesenchymal-stem-cell secretome and exosome approaches lack FDA approval for skin care and lack long-term safety data regenerative review. Regulation as biologics limits routine use despite early interest in repair and regeneration. Readers can use that caution now: Keep using proven care and ask your dermatologist before adding any probiotic or secretome product.
- Keep proven care as the base and do not replace tretinoin or prescribed antibiotics with shop products.
- Watch for the registry status to change from "Not yet recruiting" to recruiting, active, then completed.
- Judge future claims by separation from standard therapy, lesion change, side effects, and treatment length.
You Might Also Like
- The 2026 Oral Probiotic and Topical Secretome Acne Trial Protocol: Evidence Limits and Open Questions for Adults With Persistent Acne
- Skin Microbiome Outcomes in the 2026 Probiotic Acne Review: Evidence Limits and Open Questions for Adults With Persistent Acne
- Probiotics for Acne in a 2026 Systematic Review and Meta-Analysis: Evidence Limits and Open Questions for Adults With Persistent Acne